SynderBio, Inc.

Improved preparation of cell suspensions for single cell genomics

Based based in CORALVILLE, IA, SynderBio, Inc. works in university startup.

Profile

Summary: Single-cell sequencing (SCS) is a disruptive new technology that offers an unprecedented ability to interrogate the genomics (DNA, RNA) of single cells to understand the complex biologies of normal and diseased tissues. SCS is not only important for basic research, but also represents a next generation of diagnostic approaches—particularly for cancer. While multiple SCS platforms have been marketed or are under development, all of these rely on high-quality preparations of single, viable cells in a fluid suspension to enter their respective workflows. This is not a trivial undertaking, as enzymatically digested normal or diseased tissues contain dead or dying cells and cell aggregates that may confound SCS. Current cell preparation methods for SCS, such as fluorescence-activated cell-sorting (FACS) or dead-cell removal kits, are suboptimal in that they 1) often require a significant investment of time, money and/or training; 2) require multiple protocols; and/or 3) result in a poor yield of viable cells, which is particularly problematic for scarce clinical specimens. The SynderBio R&D team has developed a proprietary approach for separating cell types based on their differential responses to brief pulses of fluid shear stress (FSS). Our preliminary data supports our hypothesis that we can use this technology to rapidly (

SynderBio, Inc. is positioned in university startup, a segment that rewards a clear, focused offering.

The business is associated with CORALVILLE, IA.

It is recorded at the SBIR/STTR stage.

It has disclosed roughly $219K in funding.

Website: www.synderbio.com